Centessa's early efficacy data for narcolepsy drug Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 5 November, 2025

Health tech is in the spotlight: From wearable tech to RWE, it’s central to trends across pharma and healthcare. Join us online for an editorial briefing hosted by Endpoints journalists and guests, including a fireside chat with Hinge Health co-founder and CEO Daniel Perez. Register now.

presented by De­sign­ing for scal­a­bil­i­ty from day one: iRe­gene's foun­da­tion­al tech un­locks com­mer­cial cell ther­a­pies

spotlight Post-Hoc Live: M&A, FDA, MFN and more  — with our cousins at the FT

news Novo Nordisk sales miss underlines its need for Metsera •  'Everybody's talking about it': Metsera bidding war grips the obesity field Arena BioWorks shuts down after investors pull plug on bold bid to reinvent biotech model Centessa says early data for narcolepsy drug support registrational plans Cardio biotech Braveheart gets $185M, names Biogen CEO as its chair Exclusive: Research institute FutureHouse debuts AI scientist and for-profit spinoff

Nov 12 2:30pm ET From JP Morgan to the next wave: What's driving biotech in 2026 sponsored by Precision AQ Nov 13 11:00am ET Driving down the cost: Optimising CGT with the right CDMO partner sponsored by OXB Dec 03 10:30am ET AI & multi-omics for translational research sponsored by Precision for Medicine

Start your year where biopharma sets its agenda. Join Endpoints News and industry leaders in San Francisco as we unpack the forces shaping dealmaking, China's emerging role and regulatory shifts. Save $200 with Early Bird rates — reserve your spot today.

endpoints pharma Madrigal CEO welcomes MASH competition from Novo as demand climbs higher for Rezdiffra Lilly and Novo near White House deal on obesity drug prices As pharma pour billions in US manufacturing, CDMOs see future opportunities GoodRx wants in on TrumpRx as it grows its work with pharmaceutical manufacturers Compass plots quicker path to approval, launch readiness for depression drug Nuvation Bio backs off from head-to-head brain cancer trial

in case you missed it 1. Updated: Novo ups Metsera bid to as much as $10B in attempt to top Pfizer's new offer 2. Pfizer cuts 11 R&D programs, reports revenue decline 3. Jennifer Doudna startup launches with $82M to apply new CRISPR delivery technology to in vivo CAR-T